The local Aro expression has been shown to play a significant role in the development and progression of ERα+ breast cancer, hence aromatase inhibitors (AIs) are becoming preferred drugs to tamoxifen as they were found to be more effective than tamoxifen in blocking the progression of metastatic ERα+ breast cancer in postmenopausal patients[9]. Here, ESR1 is linked to breast cancer.